首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1691626

嵌合體抗原受體 (CAR) T 細胞治療市場：研發現狀

Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

出版日期: 2025年03月25日 | 出版商:

BCC Research | 英文 160 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球嵌合體抗原受體（CAR）T 細胞療法市場規模預計將從2024年的46億美元增至2029年終的251億美元，預測期內的年複合成長率為 40.2%。

Yescarta 市場預計將從2024年的18億美元成長到2029年終的87億美元，預測期內的年複合成長率為 36.7%。預計到2029年終，carvykti 市場規模將從2024年的7.1億美元增加到 59億美元，年複合成長率為 52.6%。

本報告涵蓋了全球嵌合體抗原受體（CAR）T細胞治療市場，並提供了市場的全面概述，包括市場影響因素和市場機會、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

市場動態
市場促進因素
癌症發生率增加
增加對 CAR-T 細胞療法研究的投資和資金
強大的開發平臺
基因工程的進展
市場限制
複雜的法律和監管程序
競爭性選擇
市場機會
精準醫療的重要性日益增加
擴大CAR-T細胞治療的應用範圍
市場挑戰
複雜的製造和供應鏈
CAR-T 細胞療法的償付挑戰

第4章新興技術與臨床試驗

世界各地進行中的臨床試驗
中國CAR-T細胞臨床試驗分佈

第5章市場區隔分析

關鍵要點
細分市場
全球 CAR-T 細胞治療市場（依產品）
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
全球 CAR-T 細胞治療市場（依適應症）
地理分佈
全球 CAR-T 細胞治療市場（依地區）
北美洲
歐洲
亞太地區
其他地區

第6章專利審查與新進展

預計有關客製化患者護理的專利訴訟將會增加
公司特定的智慧財產權和專利資訊
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc.（A Celgene Co.）
Noile-Immune Biotech
Novartis AG

第7章競爭訊息

主要企業排名
戰略考慮

第8章嵌合體抗原受體（CAR）T 細胞治療市場的永續性：ESG 視角

ESG：簡介
ESG 在製藥業中的作用
ESG績效分析
環境
社會
管治
ESG風險評估
結論

第9章附錄

調查方法
簡稱
參考
公司簡介
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS SA
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.

簡介目錄圖表

Product Code: BIO162C

The global market for CAR T-cell therapy is expected to grow from $4.6 billion in 2024 and projected to reach $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.

The global CAR T-cell therapy market for Yescarta is expected to grow from $1.8 billion in 2024 and projected to reach $8.7 billion by the end of 2029, at a CAGR of 36.7% from 2024 to 2029.

The global CAR T-cell therapy market for Carvykti is expected to grow from $710 million in 2024 and projected to reach $5.9 billion by the end of 2029, at a CAGR of 52.6% from 2024 to 2029.

Report Scope

This report incorporates an in-depth analysis of CAR T-cell therapy's current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies' business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.

Report Includes

14 data tables and 71 additional tables
Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
An analysis of patents, emerging trends and developments in the industry
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Market and Technology Background
A Brief History of CAR T-Cell Therapy
FDA Product Approvals
Other CAR T-Cell Therapies
Clinical Applications of CAR T-Cell Therapy
Adoptive Cell Transfer (ACT) Technologies

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Growing Investments and Funding in CAR T-Cell Therapy Research
Robust R&D Pipeline
Advances in Genetic Engineering
Market Restraints
Complex Legislative and Regulatory Procedures
Alternative Products from Competitors
Market Opportunities
Growing Significance of Precision Medicine
Expanding Applications for CAR T-Cell Therapy
Market Challenges
Complex Manufacturing and Supply Chain
Reimbursement Challenges for CAR T-Cell Therapy

Chapter 4 Emerging Technologies and Clinical Trials

Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Clinical Trials in China

Chapter 5 Market Segmentation Analysis

Key Takeaways
Segmentation Breakdown
Global Market for CAR T-Cell Therapy, by Product
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
Global Market for CAR T-Cell Therapy, by Indication
Geographic Breakdown
Global Market for CAR T-Cell Therapy, by Region
North America
Europe
Asia-Pacific
Rest of the World

Chapter 6 Patent Review and New Developments

Introduction
Anticipated Increase in Patent Litigation on Customized Patient Treatments
Company-specific Intellectual Property and Patent Information
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc. (A Celgene Co.)
Noile-Immune Biotech
Novartis AG

Chapter 7 Competitive Intelligence

Ranking of Leading Players
Strategic Considerations

Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective

Introduction to ESG
Role of ESG in the Pharma Industry
ESG Performance Analysis
Environmental
Social
Governance
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Abbreviations
References
Company Profiles
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.

簡介目錄圖表

List of Tables

Summary Table : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 1 : U.S. FDA-approved CAR T-cell Therapies, 2017-2022
Table 2 : Summary Classification of Tumors of the Hematopoietic and Lymphoid Tissues
Table 3 : Tumor-Associated Antigens of CAR T-Cell Targets
Table 4 : Global Cancer Statistics, 2022
Table 5 : Clinical Trials of CAR T-Cell Therapy, by Select Countries, January 2023
Table 6 : CAR T-Cell Therapy Clinical Trials Distribution, by Investigators and Collaborators, January 2023
Table 7 : Emerging CAR T-Cell Therapy Clinical Trials, by Company
Table 8 : Clinical Trials on CD19 Directed CAR T Cells in the U.S.
Table 9 : Examples of Clinical Trials on CD19-Directed CAR T Cells in China
Table 10 : Examples of Clinical Trials on CAR T Cells Targeting Non-CD19 Antigens in China
Table 11 : Examples of Clinical Trials on CAR T Cells for Solid Tumors in China
Table 12 : Clinical Trials on CAR T Cells with Fourth-Generation CARs in China
Table 13 : Global Market for CAR T-Cell Therapy, by Product, Through 2029
Table 14 : Global Market for CAR T-Cell Therapy, by Indication, Through 2029
Table 15 : Clinical Trials of CAR T-cell Therapy in Other Indications
Table 16 : Global Market for CAR T-Cell Therapy, by Region, Through 2029
Table 17 : Bluebird Bio: Patents and Patent Applications, 2012-2021
Table 18 : Celgene Corp.: Patents and Patent Applications, 2018-2021
Table 19 : Cellectis: Patents and Patent Applications, 2018-2021
Table 20 : Editas Medicine: Patent Applications, 2015-2021
Table 21 : Eureka Therapeutics: Patent Applications, 2012-2021
Table 22 : iCell Gene Therapeutics: Patent Applications, 2017-2019
Table 23 : Juno Therapeutics Inc. and Memorial Sloan Kettering Cancer Center: Patents and Patent Applications, 2000-2021
Table 24 : Noile-Immune Biotech Inc. Yamaguchi University Patent Applications, 2017
Table 25 : Novartis AG and University of Pennsylvania: Patents and Patent Applications, 2013-2021
Table 26 : Leading Companies in the CAR T-Cell Therapy Market, 2023
Table 27 : Focus Areas in ESG Metrics
Table 28 : ESG Risk Rankings for CAR T-Cell Therapy Companies, 2024*
Table 29 : Abbreviations Used in this Report
Table 30 : AbbVie Inc.: Company Snapshot
Table 31 : AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 32 : AbbVie Inc.: Product Portfolio
Table 33 : AbbVie Inc.: News/Key Developments, 2023-2024
Table 34 : Allogene Therapeutics: Company Snapshot
Table 35 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
Table 36 : Allogene Therapeutics: Product Portfolio
Table 37 : Allogene Therapeutics: News/Key Developments, 2024
Table 38 : Amgen Inc.: Company Snapshot
Table 39 : Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 40 : Amgen Inc.: Product Portfolio
Table 41 : Amgen Inc.: News/Key Developments, 2024
Table 42 : AstraZeneca: Company Snapshot
Table 43 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 44 : AstraZeneca: Product Portfolio
Table 45 : AstraZeneca: News/Key Developments, 2023-2024
Table 46 : Bluebird Bio Inc.: Company Snapshot
Table 47 : Bluebird Bio Inc.: Financial Performance, FY 2022 and 2023
Table 48 : Bluebird Bio Inc.: Product Portfolio
Table 49 : Bluebird Bio Inc.: News/Key Developments, 2020-2022
Table 50 : Bristol-Myers Squibb Co.: Company Snapshot
Table 51 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 52 : Bristol-Myers Squibb Co.: Product Portfolio
Table 53 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2024
Table 54 : Cellectis S.A.: Company Snapshot
Table 55 : Cellectis S.A.: Financial Performance, FY 2022 and 2023
Table 56 : Cellectis S.A.: Product Portfolio
Table 57 : Cellectis S.A.: News/Key Developments, 2023-2024
Table 58 : Eureka Therapeutics Inc.: Company Snapshot
Table 59 : Eureka Therapeutics Inc: Product Portfolio
Table 60 : Eureka Therapeutics Inc.: News/Key Developments, 2023-2024
Table 61 : Gilead Sciences Inc.: Company Snapshot
Table 62 : Gilead Sciences Inc.: Financial Performance, FY 2022 and 2023
Table 63 : Gilead Sciences Inc.: Product Portfolio
Table 64 : Gilead Sciences Inc.: News/Key Developments, 2022-2024
Table 65 : iCell Gene Therapeutics Inc.: Company Snapshot
Table 66 : iCell Gene Therapeutics Inc: Product Portfolio
Table 67 : iCell Gene Therapeutics Inc.: News/Key Developments, 2024
Table 68 : Johnson & Johnson Services Inc.: Company Snapshot
Table 69 : Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 70 : Johnson & Johnson Services Inc.: Product Portfolio
Table 71 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2024
Table 72 : Les Laboratoires Servier: Company Snapshot
Table 73 : Les Laboratoires Servier: Product Portfolio
Table 74 : Les Laboratoires Servier: News/Key Developments, 2024
Table 75 : Novartis AG: Company Snapshot
Table 76 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 77 : Novartis AG: Product Portfolio
Table 78 : Novartis AG: News/Key Developments, 2021-2024
Table 79 : Pfizer Inc.: Company Snapshot
Table 80 : Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 81 : Pfizer Inc.: Product Portfolio
Table 82 : Pfizer Inc.: News/Key Developments, 2023
Table 83 : Protheragen Inc.: Company Snapshot
Table 84 : Protheragen Inc.: Product Portfolio

List of Figures

Summary Figure : Global Market for CAR T-Cell Therapy, by Product, 2022-2029
Figure 1 : Historical Development of CAR T-Cell Therapy, 1992-2017
Figure 2 : Snapshot of the Market Dynamics for CAR T-Cell Therapy
Figure 3 : Estimated New Cancer Cases, 2022, 2045 and 2050
Figure 4 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Status, January 2023
Figure 5 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Study Phase, January 2023
Figure 6 : Breakdown of CAR T-Cell Therapy Clinical Trials, by Investigator Type, January 2023
Figure 7 : Global CAR T-Cell Clinical Trial Activity, by Study Start Date and Phase, 2021-2024
Figure 8 : Global Market Shares of CAR T-Cell Therapy, by Product, 2024
Figure 9 : Global Market Shares for Yescarta, by Region, 2024
Figure 10 : Global Market Shares for Kymriah, by Region, 2024
Figure 11 : Global Market Shares for Tecartus, by Region, 2024
Figure 12 : Global Market Shares for Abecma, by Region, 2024
Figure 13 : Global Market Shares for Breyanzi, by Region, 2024
Figure 14 : Global Market Shares for Carvykti, by Region, 2024
Figure 15 : Global Market Shares of CAR T-Cells Therapy, by Indication, 2024
Figure 16 : Global Market Shares of CAR T-Cell Therapy, by Region, 2024
Figure 17 : Strategic Considerations
Figure 18 : How a Strong ESG Proposition Benefits Businesses
Figure 19 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023
Figure 20 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023
Figure 21 : Amgen Inc.: Revenue Share, by Business Unit, FY 2023
Figure 22 : Amgen Inc.: Revenue Share, by Country/Region, FY 2023
Figure 23 : AstraZeneca: Revenue Share, by Business Unit, FY 2023
Figure 24 : AstraZeneca: Revenue Share, by Region/Country, FY 2023
Figure 25 : Bristol Myers Squibb Co.: Revenue Share, by Business Unit, FY 2023
Figure 26 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2023
Figure 27 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2023
Figure 28 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2023
Figure 29 : Johnson & Johnson Services Inc.: Revenue Share, by Business Unit, FY 2023
Figure 30 : Johnson & Johnson Services Inc.: Revenue Share, by Country/Region, FY 2023
Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33 : Pfizer Inc.: Revenue Share, by Business Unit, FY 2023
Figure 34 : Pfizer Inc.: Revenue Share, by Country/Region, FY 2023